| This week's sponsor is Premier Research. | |  | Tips for Achieving the Most Success in Acute-Pain Drug Trials
Sponsors studying treatments for acute pain boost their odds of success when they optimize conduct of early trials. Read our white paper for helpful tips on study design, assessment, and operations. Premier Research. It's what we do. Best. |
Featured Story | | | Monday, September 11, 2017 Shares in Kura Oncology have rocketed more than 75% after the California biotech reported it had hit the mark in a phase 2 trial of lead drug tipifarnib in head and neck cancer—before the study was fully enrolled. |
|
|
| This week's sponsor is Fierce Innovation Awards. | |  | Now Accepting Applications! Deadline: Friday, October 20th
Does your product/service have the potential to transform the biotech or pharma industry? This is your chance to submit an application and have your solution reviewed by our expert panel of judges. Apply today! |
Top Stories Monday, September 11, 2017 Idera Pharmaceuticals has posted early clinical data suggesting its TLR9 agonist improves outcomes in melanoma patients who progress after treatment with checkpoint inhibitors. The 44% overall response rate in patients treated with IMO-2125 and Yervoy has emboldened Idera to move into phase 3 early next year. Monday, September 11, 2017 Citing a crowded market of innovative meds, Janssen has canned work on its hep C cocktail program with partners Medivir and Achillion. Monday, September 11, 2017 When it comes to healthcare we know that consumers actively participate in social media to seek information and find support. More than 40% say that information from social media affects how they cope with a chronic condition, their approach to diet and exercise, the physician they select and even their decision to seek a second opinion1. Monday, September 11, 2017 Roche’s age-related macular degeneration (AMD) blockbuster-to-be has failed a phase 3 trial. The failure of lampalizumab to improve AMD-related geographic atrophy prompted Roche to stop dosing patients until it gets data from a second phase 3 trial. Monday, September 11, 2017 Shire has posted positive results for its late-stage hereditary angioedema candidate SHP616 against a dummy treatment. Monday, September 11, 2017 Fire ants may be unwelcome guests at picnics, but their venom could prove useful in treating the common autoimmune disease psoriasis. Researchers at Emory and Case Western have developed two experimental compounds inspired by the fire ant that appear promising in treating the skin disorder, which causes painful thickening and rashes. Friday, September 9, 2017 Eli Lilly is gearing up to challenge Pfizer’s Ibrance and Novartis’ Kisqali in HR-positive, HER2-negative breast cancer, and it rolled out more positive data for candidate abemaciclib over the weekend to help it get there. Saturday, September 9, 2017 The true test of a new Keytruda combination—with Incyte’s IDO1 inhibitor epacadostat—won’t deliver results till early next year. But in the meantime, Merck & Co. and Incyte unveiled some hotly anticipated data from a small, earlier-stage trial of the pairing. Monday, September 11, 2017 Here's Monday's prescription for your news of note. Resources Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: PRA Health Sciences Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
